Commercial assays for COVID-19 that are registered in Brazil have good accuracy

Added June 12, 2020

Citation: Castro R, Luz PM, Wakimoto MD, Veloso VG, Grinsztejn B, Perazzo H. COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil. The Brazilian Journal of Infectious Diseases. 2020;24(2):180-7

What is this? Efficient early detection and diagnosis of patients with COVID-19 infection is important.

In this meta-analysis, the authors searched for data on the accuracy of tests for COVID-19 that were commercially available in Brazil. They restricted their searches to data on the Brazilian Health Regulatory Agency website, and did the search on 30 March 2020. They identified 16 commercially available diagnostic tests in Brazil: 11 antibody tests, three RNA tests and two antigen tests.

What was found: At the time of this review, the included data showed that the pooled diagnostic accuracy of available diagnostic tests in Brazil was satisfactory.

At the time of this review, the included data showed that the IgG antibody, antigen, and molecular assay diagnostic tests included in the review were accurate tests.

At the time of this review, the included data showed that the IgM antibody tests in the early stages of infection gave higher rates of false-negative results.


Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.